Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 13 of 18
Next
>>
>
301 to 325 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC1806	Buparlisib	1	72	sigmoid	sigmoid	HCC1806 buparlisib 0 1 72	8	2.742	0.748	-0.369	0.226	0.931	-0.415	2.75	1.0	2.95e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
HCC1806	Buparlisib	2	72	sigmoid	sigmoid	HCC1806 buparlisib 0 2 72	8	2.827	0.759	-0.346	0.221	0.937	-0.392	2.75	1.0	2.72e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
HCC1806	Buparlisib	3	72	sigmoid	sigmoid	HCC1806 buparlisib 0 3 72	8	3.195	0.808	-0.257	0.203	0.96	-0.303	2.74	1.0	2.03e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
HCC1806	BX-912	1	72	sigmoid	sigmoid	HCC1806 BX-912 0 1 72	8	2.740	0.971	0.14	0.143	0.885	0.121	2.99	0.998	3.45e-09	NA	0.894	0.214	0.853	0.753	0.205	3.07	0.997	2.86e-08	NA
HCC1806	BX-912	2	72	sigmoid	sigmoid	HCC1806 BX-912 0 2 72	8	2.825	0.992	0.159	0.14	0.888	0.141	2.99	0.999	3.32e-09	NA	0.894	0.214	0.854	0.753	0.205	3.07	0.997	2.86e-08	NA
HCC1806	BX-912	3	72	sigmoid	sigmoid	HCC1806 BX-912 0 3 72	8	3.193	1.09	0.234	0.126	0.897	0.217	2.99	0.999	2.85e-09	NA	0.894	0.214	0.853	0.753	0.205	3.07	0.997	2.86e-08	NA
HCC1806	Alpelisib	1	72	flat	flat	HCC1806 alpelisib 0 1 72	8	2.771	Inf	0.918	0.0583	0.0	0.918	0.01	-0.337	1.0	0.94	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	Alpelisib	2	72	flat	flat	HCC1806 alpelisib 0 2 72	8	2.856	Inf	0.921	0.0566	0.0	0.921	0.01	-0.336	1.0	0.941	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	Alpelisib	3	72	flat	flat	HCC1806 alpelisib 0 3 72	8	3.224	Inf	0.93	0.0502	0.0	0.93	0.01	-0.335	1.0	0.948	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	CAL-101	1	72	flat	flat	HCC1806 idelalisib 0 1 72	8	2.695	Inf	1.02	-0.0102	0.0	1.02	0.01	-0.593	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	CAL-101	2	72	flat	flat	HCC1806 idelalisib 0 2 72	8	2.779	Inf	1.02	-0.00985	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.588	1.0	1.02
HCC1806	CAL-101	3	72	flat	flat	HCC1806 idelalisib 0 3 72	8	3.147	Inf	1.02	-0.00869	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	Everolimus	1	72	sigmoid	sigmoid	HCC1806 everolimus 0 1 72	8	2.786	Inf	0.784	0.183	0.000282	0.748	0.187	0.86	0.00277	NA	Inf	0.727	0.765	0.00022	0.729	0.377	0.879	0.00177	NA
HCC1806	Everolimus	2	72	sigmoid	sigmoid	HCC1806 everolimus 0 2 72	8	2.871	Inf	0.79	0.178	0.000277	0.79	0.365	0.879	0.00176	NA	Inf	0.727	0.765	0.000222	0.728	0.374	0.879	0.00178	NA
HCC1806	Everolimus	3	72	sigmoid	sigmoid	HCC1806 everolimus 0 3 72	8	3.239	Inf	0.813	0.159	0.000271	0.812	0.356	0.879	0.00175	NA	Inf	0.727	0.765	0.00022	0.729	0.377	0.879	0.00177	NA
HCC1806	Pictilisib	1	72	sigmoid	sigmoid	HCC1806 pictilisib 0 1 72	8	2.782	11.7	0.79	0.049	43.7	-1.0	0.831	0.811	0.00677	NA	11.3	0.734	0.935	11.3	0.0	0.849	0.773	0.0116	NA
HCC1806	Pictilisib	2	72	sigmoid	sigmoid	HCC1806 pictilisib 0 2 72	8	2.866	12.1	0.796	0.0476	45.4	-1.0	0.831	0.811	0.00671	NA	11.3	0.734	0.935	11.3	0.0	0.849	0.773	0.0116	NA
HCC1806	Pictilisib	3	72	sigmoid	sigmoid	HCC1806 pictilisib 0 3 72	8	3.234	14.1	0.818	0.0423	52.2	-0.98	0.831	0.814	0.00649	NA	11.3	0.734	0.935	11.3	0.0	0.849	0.773	0.0116	NA
HCC1806	GDC-0980	1	72	sigmoid	sigmoid	HCC1806 apitolisib 0 1 72	8	2.696	1.24	0.339	0.152	0.739	0.223	1.15	0.995	1.52e-07	NA	0.947	0.339	0.832	0.475	0.292	1.27	0.993	2.95e-07	NA
HCC1806	GDC-0980	2	72	sigmoid	sigmoid	HCC1806 apitolisib 0 2 72	8	2.781	1.32	0.355	0.148	0.746	0.241	1.15	0.995	1.49e-07	NA	0.947	0.339	0.832	0.475	0.292	1.27	0.993	2.95e-07	NA
HCC1806	GDC-0980	3	72	sigmoid	sigmoid	HCC1806 apitolisib 0 3 72	8	3.149	1.8	0.418	0.132	0.77	0.31	1.14	0.995	1.41e-07	NA	0.947	0.339	0.832	0.475	0.292	1.27	0.993	2.95e-07	NA
HCC1806	Omipalisib	1	72	sigmoid	sigmoid	HCC1806 omipalisib 0 1 72	8	2.764	0.104	-0.333	0.49	0.508	-0.746	0.577	0.98	8.23e-06	NA	0.0642	0.0481	0.54	0.0538	0.0749	0.919	0.979	9.93e-06	NA
HCC1806	Omipalisib	2	72	sigmoid	sigmoid	HCC1806 omipalisib 0 2 72	8	2.849	0.112	-0.311	0.479	0.543	-0.739	0.573	0.98	8.07e-06	NA	0.0642	0.0481	0.54	0.0538	0.0749	0.919	0.979	9.93e-06	NA
HCC1806	Omipalisib	3	72	sigmoid	sigmoid	HCC1806 omipalisib 0 3 72	8	3.217	0.147	-0.221	0.437	0.71	-0.707	0.559	0.981	7.41e-06	NA	0.0642	0.0481	0.54	0.0538	0.0749	0.919	0.979	9.93e-06	NA
HCC1806	KIN001-244	1	72	flat	flat	HCC1806 KIN001-244 0 1 72	8	2.742	Inf	0.986	0.0236	0.0	0.986	0.01	-0.0573	1.0	0.979	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972

|<
<<
Previous
Page 13 of 18
Next
>>
>
301 to 325 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)